Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events. Started Apr 2023; status: recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05818683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818683.